Free Submission Public Relations &
Deutsch English

IMPAX Laboratories, Inc. - Product Pipeline Review - 2012

IMPAX Laboratories, Inc. - Product Pipeline Review - 2012 - new company profile report published

Print article Print article
2012-12-14 08:11:15 - IMPAX Laboratories, Inc. - Product Pipeline Review - 2012 - a new company profile report on

IMPAX Laboratories, Inc. - Product Pipeline Review - 2012 - This pharmaceuticals report, "IMPAX Laboratories, Inc. - Product Pipeline Review - 2012" provides data on the IMPAX Laboratories, Inc.´s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from our proprietary databases, IMPAX Laboratories, Inc.´s corporate website, SEC filings, investor presentations and featured press releases, both from IMPAX Laboratories, Inc. and industry-specific third party sources, put together by This team.


- IMPAX Laboratories, Inc. - Brief IMPAX Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of



IMPAX Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of IMPAX Laboratories, Inc. with complete description of the product´s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IMPAX Laboratories, Inc.´s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate IMPAX Laboratories, Inc.´s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IMPAX Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IMPAX Laboratories, Inc.´s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IMPAX Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IMPAX Laboratories, Inc. and identify potential opportunities in those areas.


Current R&D Portfolio of IMPAX Laboratories, Inc.; IMPAX Laboratories, Inc. - Key Therapeutics; IMPAX Laboratories, Inc. - Pipeline Overview and Promising Molecules; IMPAX Laboratories, Inc. - News; IMPAX Laboratories, Inc. - Latest Updates; IMPAX Laboratories, Inc. - Pipeline; IMPAX Laboratories, Inc. - Discontinued/Dormant Projects

Click for report details: ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Company Profile Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact